Histology and proteinuria after renal transplantation

Transplantation Reviews

Volumn 26, Issue 1, 2012, Pages 20-26

  Serón, Daniel ^a   Burgos, Dolores ^b   Alonso, Ángel ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY;

ANTIBODY SPECIFICITY; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC HUMORAL REJECTION; CLINICAL FEATURE; DISEASE SURVEILLANCE; DRUG MEGADOSE; ELECTRON MICROSCOPY; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MEDICAL LITERATURE; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; POLYOMAVIRUS INFECTION; PROTEINURIA; RECURRENT DISEASE; REVIEW; VASCULITIS;

EID: 82955226340     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.07.009     Document Type: Review

References (45)

1. Serón D., Arias M., Campistol J.M., Morales J.M. Late renal allograft failure between 1990 and 1998 in Spain: a changing scenario. Transplantation 2003, 76:1588-1594. for the Spanish Chronic Allograft Nephropathy Group.
2. Fernández-Fresnedo G., Plaza J.J., Sanchez-Plumed J., Sanz-Guajardo A., Palomar-Fontanet R., Arias M. Nephrol Dial Transplant 2004, 19(Suppl 3):47-51.
3. Amer H., Cosio F. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009, 20:2490-2492.
4. Cherukuri A., Welberry-Smith P., Tatersall J.E., et al. The clinical significance of early proteinuria after renal transplantation. Transplantation 2010, 89:200-207.
5. Solez K., Axelsen R.A., Benediktson H., et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993, 44:411-422.
6. Serón D., Moreso F., Bover J., et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997, 51:310-316.
7. Seron D., Moreso F., Fulladosa X., Hueso M., Carrera M., Grinyo J.M. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 2002, 61:727-733.
8. Solez K., Vincenti F., Filo R.S. Histopathology findings from 2 year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK 506 Kidney Transplant Study Group. Transplantation 1998, 66:1736-1740.
9. Nankivell B.J., Borrows R.J., Fung C.L., O'Conell P.J., Allen R.D., Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326-2333.
10. Heinze G., Mitelbauer C., Regele H., et al. Angiotensin-converting enzyme inhibitor of angiotensyn type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006, 17:889-899.
11. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714.
12. Solez K., Colvin R.B., Racusen L.C., et al. Banff 05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy. Am J Transplant 2007, 7:518-526.
13. El-Zoghby Z.M., Stegall M.D., Lager D.S., et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009, 9:527-535.
14. Sellarés J., de Freitas D.J., Mengel M., et al. Inflammation lesions in kidney transplant biopsies: association with survival is due to underlying diseases. Am J Transplant 2011, 11:489-499.
15. Moreso F., Ibernon M., Gomà M., et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late allograft loss. Am J Transplant 2006, 6:747-752.
16. Amer H., Fidler M.E., Myslak M., et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007, 7:2748-2756.
17. Myslak M., Amer H., Morales P., et al. Interpreting posttransplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006, 6:1660-1665.
18. Fotheringham J., Angel C.A., McKane W. Transplant glomerulopathy: morphology, associations and mechanisms. Nephrol Clin Pract 2009, 113:1-7.
19. Gloor J.M., Sethis S., Stegall M.D., et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007, 7:2124-2132.
20. Wavamunno M.D., O'Conell P.J., Vitalone M., et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007, 7:2757-2768.
21. Debade T.S., Grande J.P., Norby S.M., Fervenza F.C., Cosio F.G. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant 2008, 8:1318-1322.
22. El-Zoghby Z.M., Grande J.P., Fraile M.G., Norby S.M., Ferventa F.C., Cosio F.G. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti CD-20 monoclonal antibodies. Am J Transplant 2009, 9:2800-2807.
23. Norby G.E., Strom E.H., Midtvedt K., et al. Recurrent lupus after kidney transplantation: a surveillance biopsy study. Ann Rheum Dis 2010, 69:1484-1487.
24. Rush D., Nicherson P., Gough J., et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998, 9:2129-2134.
25. Moreso F., Serón D., Carrera M., et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004, 78:1064-1068.
26. Rush D., Arien D., Boucher A., et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving tacrolimus and mycophenolate mofetil: a randomized study. Am J Transplant 2007, 7:2538-2545.
27. Buehring C.K., Lager D.G., Stegall M.D., et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus associated nephropathy. Kidney Int 2003, 64:665-673.
28. Schwarz C., Regele H., Huttary N., et al. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d positive chronic allograft nephropathy. Wien Klin Wochenschr 2006, 118:397-404.
29. Sberro-Soussan R., Zuber J., Suberbielle-Boissel, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor specific anti-HLA antibodies. Am J Transplant 2010, 10:681-686.
30. Briganti E.M., Russ G.R., McNeil J.J., Atkins R.C., Chadban S.J. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002, 347:103-109.
31. Choi B.Y., Chan T.M., Lai K.N. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006, 6:2535-2542.
32. Sprangers B., Lefkowitz G.I., Cohen S.D., et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin Am Soc Nephrol 2010, 5:790-797.
33. Ruggenenti P., Chiurchiu C., Brusegan, et al. Rituximab in idiopathic membranous nephropathy: a one year prospective study. J Am Soc Nephrol 2003, 14:1851-1857.
34. Segarra A., Praga M., Ramos N., et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor dependent patients. Clin J Am Soc Nephrol 2001, 4:1017-1019.
35. Geetha D., Seo P., Specks U., Ferventa F.C. Successful induction of remission with rituximab for relapsing ANCA associated vasculitis post-kidney transplant: report of two cases. Am J Transplant 2007, 7:2821-2825.
36. Canaud G., Zuber J., Sberro R., et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis: recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant 2009, 9:1081-1086.
37. Mulay A.V., van Walrven, Knoll G.A. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant 2009, 9:804-811.
38. Berthoux F., El Deeb S., Mariat C., Diconne E., Laurent B., Thibaudin L. Antithymocyte globulin (ATG) induction therapy and disease recurrence with primary IgA nephropathy. Transplantation 2008, 85:1505-1507.
39. Naesens M., Kuypers D.R., Saewal M., et al. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009, 4:481-508.
40. Faul C., Donnelly M., Merscher-Domez S., et al. The actin skeleton of kidney podocytes is a direct target of the anti-proteinuric effect of cyclosporine A. Nat Med 2008, 14:931-938.
41. Diekman F., Budde K., Oppenheimer F., Fritsche L., Neumayer H.H., Campistol J.M. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004, 4:1869-1875.
42. Letavernier E., Legendre C. mTOR inhibitors-induced proteinuria: mechanisms, significance and management. Transplant Rev (Orlando) 2008, 22:125-130.
43. Letavernier E., Bruneval P., Vandermeeersch, et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009, 24:630-638.
44. Straathof-Galema L., Wetzeis J.F., Dijkam H.B., Steenbergen E.J., Hilbrands L.B. Sirolimus associated heavy proteinuria in renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006, 6:429-433.
45. Stallone G., Infante B., Pontrelli P., et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 2011, [epub ahead of print].